Literature DB >> 14968328

[Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].

C Pföhler1, S Steinhäuser, A Wagner, S Ugurel, W Tilgen.   

Abstract

Multiple cutaneous satellite and in-transit metastases of melanoma without involvement of lymph nodes or other organs are a challenge especially when they occur in elderly inoperable patients with multiple internal diseases. In this particular situation, intralesional application of interleukin-2 may represent an effective alternative to systemic chemo- or immunotherapy as it can be performed on an out-patient basis and has few side effects. We treated two elderly female patients with multiple cutaneous metastases of malignant melanoma with intra- and perilesional application of interleukin-2 (3 x 6-12 Mio IE) over 12 weeks and achieved a complete remission of these metastases. In follow-up biopsies, no viable tumor cells were found. Despite a slight burning at the injection side and a transient local inflammatory reaction, the therapy was well tolerated in both cases after premedication with paracetamol 500 mg orally and pretreatment of the injection site with a cream containing lidocaine and prilocaine. No systemic side effects were observed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968328     DOI: 10.1007/s00105-003-0620-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  15 in total

1.  Topical imiquimod in the treatment of metastatic melanoma to skin.

Authors:  Ingrid H Wolf; Josef Smolle; Barbara Binder; Lorenzo Cerroni; Erika Richtig; Helmut Kerl
Journal:  Arch Dermatol       Date:  2003-03

2.  Safety and efficacy of isolated limb perfusion in elderly melanoma patients.

Authors:  E M Noorda; B C Vrouenraets; O E Nieweg; A N van Geel; A M M Eggermont; B B R Kroon
Journal:  Ann Surg Oncol       Date:  2002-12       Impact factor: 5.344

3.  Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread.

Authors:  S Ugurel; A Wagner; C Pföhler; W Tilgen; U Reinhold
Journal:  Br J Dermatol       Date:  2002-09       Impact factor: 9.302

4.  Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.

Authors:  L Ridolfi; R Ridolfi; A Ascari-Raccagni; M Fabbri; S Casadei; A Gatti; G Trevisan; M G Righini
Journal:  J Eur Acad Dermatol Venereol       Date:  2001-05       Impact factor: 6.166

5.  Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

Authors:  U Keilholz; C Conradt; S S Legha; D Khayat; C Scheibenbogen; N Thatcher; S H Goey; M Gore; T Dorval; B Hancock; C J Punt; R Dummer; M F Avril; E B Bröcker; A Benhammouda; A M Eggermont; M Pritsch
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

Review 6.  Perspectives of cytokine treatment in malignant skin tumors.

Authors:  C Garbe
Journal:  Recent Results Cancer Res       Date:  1995

7.  [Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates].

Authors:  K Assmann; D Nashan; S Grabbe; T A Luger; D Metze
Journal:  Hautarzt       Date:  2002-08       Impact factor: 0.751

8.  The impact of surgery on the course of melanoma.

Authors:  Ferdy J Lejeune
Journal:  Recent Results Cancer Res       Date:  2002

9.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

10.  Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).

Authors:  A Hauschild; C Garbe; W Stolz; U Ellwanger; S Seiter; R Dummer; S Ugurel; G Sebastian; D Nashan; R Linse; W Achtelik; P Mohr; R Kaufmann; M Fey; J Ulrich; W Tilgen
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

View more
  1 in total

1.  Local therapy of cancer with free IL-2.

Authors:  Willem Den Otter; John J L Jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan Willem Koten
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.